Create account

Coverage dated November 6, 2026

Eli Lilly is partnering with Hims & Hers to sell its weight loss drugs

Headline from Quartz

The agreement covers Zepbound and Foundayo for patients who pay out of pocket through the telehealth platform

Quartz's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Read the reports

Reports & sources

3 articles, oldest first.

  1. Bloomberg

    Lilly, Hims Join Forces to Reach More Weight-Loss Drug Patients (opens Bloomberg)

    Published

    Bloomberg's feed description

    Eli Lilly & Co. is teaming up with Hims & Hers Health Inc. to make its blockbuster obesity medicines more widely available, tapping into the telehealth company’s vast customer base to boost sales of drugs including its new weight-loss pill Foundayo.

  2. Quartz

    Eli Lilly is partnering with Hims & Hers to sell its weight loss drugs (opens Quartz)

    Published

    Quartz's feed description

    The agreement covers Zepbound and Foundayo for patients who pay out of pocket through the telehealth platform

  3. Investor's Business Daily

    Hims & Hers Surges On 'Surprising And Inevitable' Deal With Eli Lilly (opens Investor's Business Daily)

    Published

    Investor's Business Daily's feed description

    Hims & Hers Health inked a deal with Eli Lilly on Friday to sell the company's obesity drugs, further entrenching itself in the GLP-1 space.

Eli Lilly is partnering with Hims & Hers to sell its weight loss drugs | Since Then